Success Metrics

Clinical Success Rate
86.9%

Based on 279 completed trials

Completion Rate
87%(279/321)
Active Trials
59(11%)
Results Posted
39%(110 trials)
Terminated
42(8%)

Phase Distribution

Ph phase_2
95
18%
Ph phase_3
97
19%
Ph phase_1
47
9%
Ph phase_4
172
33%
Ph early_phase_1
19
4%
Ph not_applicable
71
14%

Phase Distribution

66

Early Stage

95

Mid Stage

269

Late Stage

Phase Distribution501 total trials
Early Phase 1First-in-human
19(3.8%)
Phase 1Safety & dosage
47(9.4%)
Phase 2Efficacy & side effects
95(19.0%)
Phase 3Large-scale testing
97(19.4%)
Phase 4Post-market surveillance
172(34.3%)
N/ANon-phased studies
71(14.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.3%

279 of 339 finished

Non-Completion Rate

17.7%

60 ended early

Currently Active

59

trials recruiting

Total Trials

518

all time

Status Distribution
Active(75)
Completed(279)
Terminated(60)
Other(104)

Detailed Status

Completed279
unknown104
Recruiting48
Terminated42
Withdrawn18
Not yet recruiting15

Development Timeline

Analytics

Development Status

Total Trials
518
Active
59
Success Rate
86.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 119 (3.8%)
Phase 147 (9.4%)
Phase 295 (19.0%)
Phase 397 (19.4%)
Phase 4172 (34.3%)
N/A71 (14.2%)

Trials by Status

active_not_recruiting112%
withdrawn183%
completed27954%
not_yet_recruiting153%
terminated428%
unknown10420%
recruiting489%
enrolling_by_invitation10%

Recent Activity

Clinical Trials (518)

Showing 20 of 518 trialsScroll for more
NCT07644234Phase 4

Platelet Aggregation Function-Guided De-Escalation Antiplatelet Therapy in Patients With Acute Ischemic Stroke

Not Yet Recruiting
NCT07642427Phase 4

Early Prophylactic Aspirin for Aneurysmal Subarachnoid Hemorrhage

Not Yet Recruiting
NCT04796714Phase 4

AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE

Recruiting
NCT06486792Phase 4

Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation

Recruiting
NCT04464070Early Phase 1

Pathways of Eicosanoid Metabolism

Enrolling By Invitation
NCT07617870Phase 3

Pro-urokinase for Extended-Window Posterior Circulation Stroke

Not Yet Recruiting
NCT05411718Phase 2

A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome

Recruiting
NCT07613840Not Applicable

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease

Recruiting
NCT02965703Phase 2

Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma

Active Not Recruiting
NCT07597239Not Applicable

Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization

Active Not Recruiting
NCT03805932Phase 1

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

Active Not Recruiting
NCT07525635Early Phase 1

Aspirin Dosing in Pregnancy

Recruiting
NCT05056896Early Phase 1

ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension

Active Not Recruiting
NCT07572747Phase 3

Aspirin Versus Clopidogrel in Chronic Coronary Syndrome in Arabian Gulf Countries

Not Yet Recruiting
NCT05955365Phase 4

Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation

Recruiting
NCT03907046Phase 3

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

Recruiting
NCT05625724Phase 3

Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes After Assisted Reproductive Technology

Recruiting
NCT04770012Phase 3

AERIAL Trial: Antiplatelet Therapy in Heart Transplantation

Recruiting
NCT06710184Phase 4

Treatment With Aspirin Alone Versus Aspirin in Combination With Fondaparinux Before Early Coronary Assessment in Patients With Non-ST-Elevation Myocardial Infarction

Recruiting
NCT02521285Phase 2

Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation

Active Not Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
518